» Articles » PMID: 36277890

Adipose-Derived Stem Cell Exosomes Inhibit Hypertrophic Scaring Formation by Regulating Th17/Treg Cell Balance

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2022 Oct 24
PMID 36277890
Authors
Affiliations
Soon will be listed here.
Abstract

Aiming to reveal the role of ADCS-Exos in secretion of inflammatory factors, Th17 and regulatory T (Treg) cell differentiation from naïve CD4+ T cells in hypertrophic scaring formation and maturation is explored. ELISA, qRT-PCR, and immunoblotting are performed to assay the local inflammatory factors IL-6, IL-10, IL-17A, and TNF-, and transcriptional factors of RORt and Foxp3, in scaring tissue from patients and mice wound models treated with or without ADCS-Exos. Immunohistochemistry staining and immunoblotting are conducted to assay the extracellular matrix (ECM) deposition in vitro and in vivo. The results show that IL-6, IL-10, IL-17A, TNF-, RORt, and Foxp3 are increased on mRNA and protein levels in hypertrophic scaring compared with atrophic scaring and normal skin. Naïve CD4 T cells treated with ADCS-Exos in vitro can produce significantly less IL-6, IL-17A, TNF-, and RORt and more IL-10 and Foxp3 on mRNA and protein levels. In addition, mice in ADSC-Exos-treated group demonstrate less collagen deposition; decreased IL-17A, TNF-, and RORt; and increased IL-10 and Foxp3 production.

Citing Articles

Application and progress of new technologies and new materials in the treatment of pathological scar.

Liu Y, Wang S, Yang F, Wang X, Zhang J, Han X Front Chem. 2024; 12:1389399.

PMID: 38752199 PMC: 11094272. DOI: 10.3389/fchem.2024.1389399.


A systematic review of the efficacy, safety and satisfaction of regenerative medicine treatments, including platelet-rich plasma, stromal vascular fraction and stem cell-conditioned medium for hypertrophic scars and keloids.

Jafarzadeh A, PourMohammad A, Goodarzi A Int Wound J. 2023; 21(4):e14557.

PMID: 38126221 PMC: 10961894. DOI: 10.1111/iwj.14557.


Retracted: Adipose-Derived Stem Cell Exosomes Inhibit Hypertrophic Scaring Formation by Regulating Th17/Treg Cell Balance.

International B Biomed Res Int. 2023; 2023:9897257.

PMID: 37475817 PMC: 10356299. DOI: 10.1155/2023/9897257.


Advances in Immunomodulatory Mechanisms of Mesenchymal Stem Cells-Derived Exosome on Immune Cells in Scar Formation.

Zhao W, Zhang H, Liu R, Cui R Int J Nanomedicine. 2023; 18:3643-3662.

PMID: 37427367 PMC: 10327916. DOI: 10.2147/IJN.S412717.


Leveraging Exosomes as the Next-Generation Bio-Shuttles: The Next Biggest Approach against Th17 Cell Catastrophe.

Samarpita S, Li X Int J Mol Sci. 2023; 24(8).

PMID: 37108809 PMC: 10142210. DOI: 10.3390/ijms24087647.

References
1.
Zhu X, Zhu J . CD4 T Helper Cell Subsets and Related Human Immunological Disorders. Int J Mol Sci. 2020; 21(21). PMC: 7663252. DOI: 10.3390/ijms21218011. View

2.
Ranganath S, Levy O, Inamdar M, Karp J . Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10(3):244-58. PMC: 3294273. DOI: 10.1016/j.stem.2012.02.005. View

3.
Zhang Q, Liu L, Yong Q, Deng J, Cao W . Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model. Stem Cell Res Ther. 2015; 6:145. PMC: 4539671. DOI: 10.1186/s13287-015-0133-y. View

4.
Wang Z, Zhao W, Cao Y, Liu Y, Sun Q, Shi P . The Roles of Inflammation in Keloid and Hypertrophic Scars. Front Immunol. 2020; 11:603187. PMC: 7746641. DOI: 10.3389/fimmu.2020.603187. View

5.
He B, Wang Y, Shao N, Chang H, Cheng Y . Polymers modified with double-tailed fluorous compounds for efficient DNA and siRNA delivery. Acta Biomater. 2015; 22:111-9. DOI: 10.1016/j.actbio.2015.04.037. View